In recent years, the incidence of non-Hodgkin lymphoma (NHL) is on the rise. Among the newly diagnosed NHL patients, 3 %-10 % are mantle cell lymphoma (MCL), which is common in middle-aged and elderly men, and the incidence of extranodal aggression is more in stage Ⅲ or Ⅳ. MCL has clinical and pathological features of the invasiveness in invasive lymphoma and the incurability in indolent lymphoma. Although the application of new drugs has made more progress in the treatment of MCL, the overall survival rate is not good; the majority of patients relapse after treatment, and there are no standard treatment regimens. The progresses in MCL will be summarized in this paper based on the reports in the 60th American Society of Hematology (ASH) Annual Meeting.